| Shortcuts:2012 2011 2010 2009 2008 2007 2005 2004 2003 |
| 2012 |
| • |
Positive Results from Phase 1/2 POSEIDON Trial Demonstrate Donor (Allogeneic) Adult Mesenchymal Stem Cells (MSCs) Utilizing BioCardia Catheter Delivery System Are Similarly Effective as Patients’ Own Stem Cells in Treating Ischemic Heart Failure |
| • |
Juventas Therapeutics doses first patient in Phase II STOP-HF trial |
| • |
BioCardia and Juventas Announce Phase II Development Program of JVS-100 delivered with the Helical Infusion System to treat Heart Failure |
| 2011 |
| • |
Two Year Follow up Safety Data on Helical Infusion System reported in December 2011 Issue of EuroIntervention |
| • |
Featured in Circulation Research: "Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy Functional Recovery and Reverse Remodeling” |
| • |
BioCardia elects Industry Veteran, Jay M. Moyes, to Board of Directors |
| 2010 |
| • |
BioCardia Announces CE Mark Approval |
| • |
BioCardia Announces Issuance of Patents Related to Cardiac Regenerative Medicine Using Cell Therapy |
| 2009 |
| • |
University of Miami announces successful completion of safety phase of autologous stem cells in Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT); sixty patient randomized portion of trial has been initiated |
| • |
TABMMI Heart Failure Stem Cell Clinical Trial Results Presented; Improvements Sustained at Three Year Follow-up |
| • |
Novel UM Stem Cell Trial Completes Early Safety Phase |
| 2008 |
| • |
TAC-HFT Stem Cell Trial Treats First Heart Failure Patient |
| • |
Stem Cell Researchers At UM Enrolling Patients In Heart Failure Study - Catheter Injection System To Be Used |
| • |
BioCardia and the University of Miami Receive FDA Clearance to Initiate Co-Sponsored Heart Failure Stem Cell Clinical Trial Comparing Two Cell Populations |
| • |
BioCardia Completes $7.4 Million Private Equity Financing Successful Round Follows Completion of Phase I Clinical Trial Enrollment and Two Year Follow-up Data Publication on First Cohort |
| • |
BioCardia announces completion of enrollment of TABMMI cardiac stem cell trial |
| 2007 |
| • |
BioCardia announces completion of two year follow-up for patients enrolled in the TABMMI trial |
| • |
BioCardia announces peer reviewed publication of one year follow-up data for stem cell clinical trial to treat chronic heart disease |
| 2005 |
| • |
BioCardia announces completion of enrollment for Phase I adult stem cell clinical trial to treat chronic heart disease |
| • |
BioCardia, Inc. and Symphony Medical, Inc. announce a mutually exclusive agreement for development and commercialization of a combination product that combines Symphony Medical's biotherapeutic technology and BioCardia device delivery technology for the treatment of cardiac conduction disorders |
| 2004 |
| • |
BioCardia announces issuance of two patents on biotherapeutic delivery to the heart |
| • |
BioCardia announces issuance of patents related to cell and gene therapy and drug eluting stents |
| • |
Thoratec Corporation Announces Equity Investment in Emerging Heart Failure Technology - BioCardia Is Developing Tools for Delivery of Biotherapeutic Compounds to the Heart |
| • |
Featured in "Convergence and Complexity in Cardiac Regeneration" START UP, April 2004 |
| 2003 |
| • |
Featured in "Cardiac Gene Therapy: Combination Products Next Frontier?" |
